.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

OncLive® Clinical Updates: Cardiovascular Adverse Events with BTK Inhibitors in B Cell Malignancies

EP. 1: Dr. Rhee on the Benefit of Zanubrutinib Vs Ibrutinib in R/R CLL

February 8th 2023

June-Wha Rhee, MD, discusses the benefit of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia, as well as the incidence of cardiac disorders associated with the BTK inhibitors.

EP. 2: Cardiovascular Adverse Events with BTK Inhibitors in B-Cell Malignancies

April 13th 2023